Asher Bio
We build better immunotherapies
About Asher Bio
Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases.
Asher Bio is backed by Third Rock Ventures and is located in South San Francisco.
Company details
Funding
Total raised
$219M
Last stage
Series C
Investors
Founders
Andy Yeung
Co-founded Asher Bio in 2019 after spending ten years at Pfizer, most recently as Director of Cancer Immunology Discovery. Serves as CTO and Board Observer, responsible for drug concept initiation and leading engineering and technology development of antibody and cytokine candidates.
LinkedIn
Ivana Djuretic
Co-founded Asher Bio in 2019 after serving as Head of Cytokine Biology at Pfizer's Cancer Immunology Discovery Unit. Currently CEO, Board Member, and Co-Founder, leading discovery, immuno-biology, and early development of Asher Bio's immuno-oncology and autoimmunity programs.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.